Latanoprostene bunod

Latanoprostene bunod
Names
Trade names	Vyzulta
Other names	BOL-303259-X
	IUPAC name 4-Nitrooxybutyl (Z)-7-[(1R,2R,3R,5S)-3,5-dihydroxy-2-[(3R)-3-hydroxy-5-phenylpentyl]cyclopentyl]hept-5-enoate;
Clinical data
Drug class	Prostaglandin
Main uses	Increased intraocular pressure
Side effects	Eye pain, eye redness
External links
AHFS/Drugs.com	Monograph
Legal
Legal status	US: ℞-only ;
Chemical and physical data
Formula	C27H41NO8
Molar mass	507.624 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES C1[C@H]([C@@H]([C@H]([C@H]1O)C/C=C\CCCC(=O)OCCCCO[N+](=O)[O-])CC[C@H](CCC2=CC=CC=C2)O)O;
	InChI InChI=1S/C27H41NO8/c29-22(15-14-21-10-4-3-5-11-21)16-17-24-23(25(30)20-26(24)31)12-6-1-2-7-13-27(32)35-18-8-9-19-36-28(33)34/h1,3-6,10-11,22-26,29-31H,2,7-9,12-20H2/b6-1-/t22-,23+,24+,25-,26+/m0/s1; Key:LOVMMUBRQUFEAH-UIEAZXIASA-N;

Latanoprostene bunod, sold under the brand name Vyzulta, is a medication used to treat increased intraocular pressure in open-angle glaucoma and ocular hypertension.^[1] It is used as an eye drop.

Common side effects include eye pain and eye redness.^[1] Other side effects may include bacterial keratitis, macular edema, darkening of the skin around the eye, and eyelash changes.^[1] It is a prostaglandin which increases outflow through the trabecular meshwork and uveoscleral pathway.^[1]^[2]

Latanoprostene bunod was approved for medical use in the United States in 2017.^[1] In the United States it costs about 230 USD for a 2.5 ml bottle as of 2021.^[3] As of 2021 it is not commercially available in the United Kingdom or Europe.^[4]

References

↑ ^1.0 ^1.1 ^1.2 ^1.3 ^1.4 ^1.5 ^1.6 ^1.7 "Latanoprostene Bunod Monograph for Professionals". Drugs.com. Archived from the original on 4 March 2021. Retrieved 21 November 2021.
↑ Hoy SM (May 2018). "Latanoprostene Bunod Ophthalmic Solution 0.024%: A Review in Open-Angle Glaucoma and Ocular Hypertension". Drugs. 78 (7): 773–780. doi:10.1007/s40265-018-0914-6. PMC 5976683. PMID 29761382.
↑ "Vyzulta Prices, Coupons & Patient Assistance Programs". Drugs.com. Archived from the original on 16 May 2021. Retrieved 21 November 2021.
↑ "Latanoprostene bunod". SPS - Specialist Pharmacy Service. 25 January 2016. Archived from the original on 21 November 2021. Retrieved 21 November 2021.

External links

This pharmacology-related article is a stub. You can help MDWiki by expanding it.

[AHFS2021-1] 1.0 ^1.1 ^1.2 ^1.3 ^1.4 ^1.5 ^1.6 ^1.7 "Latanoprostene Bunod Monograph for Professionals". Drugs.com. Archived from the original on 4 March 2021. Retrieved 21 November 2021.

[Hoy-2] Hoy SM (May 2018). "Latanoprostene Bunod Ophthalmic Solution 0.024%: A Review in Open-Angle Glaucoma and Ocular Hypertension". Drugs. 78 (7): 773–780. doi:10.1007/s40265-018-0914-6. PMC 5976683. PMID 29761382.

[3] "Vyzulta Prices, Coupons & Patient Assistance Programs". Drugs.com. Archived from the original on 16 May 2021. Retrieved 21 November 2021.

[4] "Latanoprostene bunod". SPS - Specialist Pharmacy Service. 25 January 2016. Archived from the original on 21 November 2021. Retrieved 21 November 2021.

[1]

[2]

[3]

[4]

Latanoprostene bunod

References

External links

Navigation menu

Search